Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04244500
Other study ID # UMR893958
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 27, 2020
Est. completion date August 2020

Study information

Verified date January 2020
Source University of Rostock
Contact Martin Bienengraeber, Dr.
Phone +49 381 494 5031
Email dekanat.forschung@med.uni-rostock.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study plans to conduct enhanced influenza surveillance at a hospital emergency department level independent of underlying influenza-like symptoms.


Description:

Study objectives

Primary:

- Measure the proportion of non-traumatic emergency department (ED) visits infected with influenza during the peak of the influenza season

Secondary:

- Describe the demographic and medical profile of influenza-related and non-influenza-related visits

- Identify socio-demographic or other risk factors associated with ED visit outcome

- Describe the influenza positivity rate among ED visits for different causes

- Measure the proportion of influenza positive patients without classical ILI symptoms


Recruitment information / eligibility

Status Recruiting
Enrollment 2500
Est. completion date August 2020
Est. primary completion date April 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All adult patients seeking care at participating ED during the influenza season

- Participants and/or guardian providing informed consent and/or assent, as appropriate, to participate.

Exclusion Criteria:

- Individuals reporting having suffered a traumatic injury without other conditions.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
swab sampling
Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections

Locations

Country Name City State
Germany University of Rostock Rostock

Sponsors (4)

Lead Sponsor Collaborator
University of Rostock Klinikum Ernst von Bergmann Potsdam, Klinikum Suedstadt, Rostock, Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary influenza status at admission to ED (positive vs. negative) proportion of non-traumatic emergency department (ED) visits infected with influenza during the peak of the influenza season at admission to ED
Secondary demographic and medical profile demographic and medical profile of influenza-related and non-influenza-related visits at admission to ED
Secondary socio-demographic or other risk factors Identify socio-demographic or other risk factors associated with ED visit outcome at admission to ED
Secondary influenza without classical symptoms of influenza-like illness Measure the proportion of influenza positive patients without classical ILI symptoms at admission to ED
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Completed NCT03275389 - A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years Phase 1
Completed NCT05981846 - A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 Phase 2
Completed NCT05044195 - A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age Phase 3
Completed NCT02914275 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age. Phase 3
Completed NCT04590066 - Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy N/A
Recruiting NCT03778203 - Development of Childhood Anti-influenza Immunity Phase 4
Completed NCT04527614 - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection N/A
Terminated NCT03658629 - Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults Phase 2
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02998996 - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU Phase 1/Phase 2
Completed NCT02867358 - A Clinical Trial of KT07 Capsule in the U.S.A Phase 2
Withdrawn NCT02883972 - Childhood Influenza Immunisation Invitation Trial in Schools N/A
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Completed NCT02545543 - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age Phase 3
Completed NCT02212106 - A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years Phase 4
Completed NCT02621164 - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents Phase 3
Completed NCT02243774 - Mail Outreach To Increase Vaccination Acceptance Through Engagement N/A
Completed NCT02344134 - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects Phase 3